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Introduction
A fundamental issue in endocrine cell neoplasia is how
two separate properties, abnormal cell proliferation
and aberrant control of hormonal secretion, develop
and interrelate. Primary hyperparathyroidism, or
hypercalcemia due to excessive secretion of parathyroid
hormone (PTH) by one or more parathyroid tumors,
offers an excellent model system in which this basic
problem can be examined. Not only does a proliferative
defect leading to parathyroid hypercellularity exist in
this common disorder, but studies of pathological
parathyroid cells from human parathyroid adenomas
in vivo and patients with primary hyperparathyroidism
in vivo have revealed abnormalities in the feedback sys-
tem (“set-point pathway”) through which extracellular
calcium regulates PTH release (1, 2).
A link between mechanisms controlling prolifera-
tion and hormonal production/secretion is also evi-
dent in normal parathyroid cells, which respond to the
stimulus of chronic hypocalcemia not only by an
appropriate homeostatic increase in PTH release but
with a secondary expansion of parathyroid cell mass.
In fact, it has been hypothesized that most parathyroid
tumors are caused by acquired mutation(s) in genes of
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The relationship between abnormal cell proliferation and aberrant control of hormonal secretion is a
fundamental and poorly understood issue in endocrine cell neoplasia. Transgenic mice with parathy-
roid-targeted overexpression of the cyclin D1 oncogene, modeling a gene rearrangement found in
human tumors, were created to determine whether a primary defect in this cell-cycle regulator can
cause an abnormal relationship between serum calcium and parathyroid hormone response, as is typ-
ical of human primary hyperparathyroidism. We also sought to develop an animal model of hyper-
parathyroidism and to examine directly cyclin D1’s role in parathyroid tumorigenesis. Parathyroid
hormone gene regulatory region–cyclin D1 (PTH–cyclin D1) mice not only developed abnormal
parathyroid cell proliferation, but also developed chronic biochemical hyperparathyroidism with char-
acteristic abnormalities in bone and, notably, a shift in the relationship between serum calcium and
PTH. Thus, this animal model of human primary hyperparathyroidism provides direct experimental
evidence that overexpression of the cyclin D1 oncogene can drive excessive parathyroid cell prolifera-
tion and that this proliferative defect need not occur solely as a downstream consequence of a defect
in parathyroid hormone secretory control by serum calcium, as had been hypothesized. Instead, pri-
mary deregulation of cell-growth pathways can cause both the hypercellularity and abnormal control
of hormonal secretion that are almost inevitably linked together in this common disorder.
J. Clin. Invest. 107:1093–1102 (2001).
See related Commentary on pages 1079–1080.
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the set-point pathway, with this abnormal PTH
response to the ambient calcium level actually provid-
ing the stimulus to abnormal tumor cell proliferation
(3). Whether excess parathyroid endocrine cell prolif-
eration is the result or cause of abnormal hormonal
regulation remains controversial.
Two specific genes have been implicated in the patho-
genesis of parathyroid adenomas: the cyclin D1/PRAD1
oncogene (4) and the MEN1 tumor-suppressor gene (5).
Cyclin D1 is an integral component of the cell-cycle reg-
ulatory machinery, acting with cyclin-dependent kinas-
es to drive progression through the G1/S checkpoint (6).
The cyclin D1 oncogene is activated in a subset of
parathyroid adenomas, in which a chromosome 11
inversion brings the cyclin D1 gene under the influence
of the 5′-regulatory region of the PTH gene, leading to
cyclin D1 overexpression (4, 7). Cyclin D1 overexpression
is found in 20–40% of parathyroid adenomas (8–10). To
define the role of cyclin D1 in parathyroid neoplasia and
to investigate the relationship between proliferative and
hormonal regulatory abnormalities in this disease, we
generated transgenic mice that overexpress the cyclin D1
oncogene in parathyroid glands, using a transgene that
mimics the human PTH–cyclin D1 gene rearrangement.
Methods
Transgene construct and generation of transgenic mice. To target
transgene expression to parathyroid tissue, we used the 
5′-regulatory region of the human PTH gene. This choice
was based on the strong and highly restricted tissue speci-
ficity of PTH gene expression in parathyroid tissue and the
clonal juxtaposition of the upstream PTH region with
cyclin D1 in human tumors. Because the precise regulato-
ry elements that govern tissue specificity of PTH gene
expression are unknown, we selected approximately 5 kb
of the PTH upstream region as the targeting component
of the transgene, given that this length would encompass
many of the tissue-specific enhancer elements used suc-
cessfully in transgenic experiments (11–13). Specifically, a
5.2-kb BglII–BglII 5′-regulatory fragment of the human
PTH gene (14) (kindly provided by Henry Kronenberg,
Massachusetts General Hospital), consisting of 5.1 kb of
flanking sequence and the first 66 bp of untranslated exon
1 (full sequence: GenBank accession number AF346654)
was ligated to a 16-kb human genomic cyclin D1 fragment
including all exons and introns, 1.1-kb 5′-flanking region,
and 1-kb 3′-flanking region (15). The genomic cyclin D1
sequence, rather than its cDNA, was chosen to most faith-
fully represent the PTH–cyclin D1 gene rearrangement
found in human tumors. Because the cyclin D1 compo-
nent of the transgene included its own promoter, the
transgenic cyclin D1 transcript was expected to originate
from this promoter and to rely on the PTH sequences for
their longer-range tissue-specific enhancer(s); indeed,
sequenced transgene-derived cDNAs from parathyroid tis-
sue contained only cyclin D1 and no contribution from
the PTH 5′ untranslated region.
This PTH–cyclin D1 construct was cloned into pBlue-
script SK+ (Stratagene, La Jolla, California, USA) with
synthesized NruI sites in the polylinker region (Figure
1). The 21-kb transgene DNA fragment was released by
NruI digestion, isolated by low–melting point agarose
gel electrophoresis, and further purified by cesium chlo-
ride centrifugation and extensive dialysis. The transgene
was microinjected into pronuclei of fertilized eggs from
FVB/N mice, and injected eggs were transplanted to
pseudopregnant foster mothers and allowed to develop
to term. Tail DNA was analyzed by Southern blot analy-
sis using the human cyclin D1 cDNA as a probe or PCR
using the following primers: exon 1A, 5′-GGGGCAGCA-
GAAGCGAGAGC-3′; exon 1B, 5′-GGGGTGAGTGCAAA-
GAAAC-3′ (16). All mice were provided with the Prolab
RMH 3000 regular diet containing 0.98% calcium and
0.74% phosphorus (PMI Nutrition International, Rich-
mond, Indiana, USA) and water ad libitum. Studies
were approved by the appropriate institutional animal
care committees at the University of Connecticut
Health Center and the Massachusetts General Hospital.
Histologic examination of parathyroid glands and in situ
hybridization. At necropsy mice were fixed in 10% phos-
phate-buffered formalin. The thyroid, parathyroids, tra-
chea, esophagus, muscle, and adipose tissue were dis-
sected en bloc, processed, and embedded in paraffin wax.
To examine the complete parathyroid glands, serial sec-
tions were cut to a thickness of 5 µm and processed
either for morphological hematoxylin/eosin or in situ
hybridization. In situ hybridization for the human cyclin
D1 gene was performed using complementary antisense
and negative control sense 35S-labeled riboprobes (17),
which were transcribed from the plasmid containing the
human cyclin D1 cDNA (pPL-8) (4). Dark-field views were
counterstained with hematoxylin and eosin. The histo-
logic identification of parathyroid glands was confirmed
by in situ hybridization for PTH gene expression using a
rat PTH plasmid template and riboprobe.
Immunohistochemical analysis of cyclin D1 expression.
Immunohistochemical analysis for cyclin D1 was per-
formed on 5-µm-thick frozen tissue sections using the
avidin-biotin peroxidase-complex method. Initially,
endogenous peroxidase activity in tissue was ablated
with 3% hydrogen peroxide in methanol for 5 minutes.
Nonspecific protein binding was then suppressed
using 10% goat serum for 30 minutes. Tissue sections
were incubated overnight at 4°C with biotinylated
mouse monoclonal anti-human cyclin D1 Ab at 1:50
dilution (clone 5D4 kindly provided by Masao Seto,
Aichi Cancer Center, Nagoya, Japan; commercially
available through Immuno-Biological Laboratories,
Fujioka, Japan). Characterization and specificity of the
Ab has been described elsewhere (18, 19). The next day,
slides were washed with PBS. Sections were then incu-
bated with avidin-biotin peroxidase complex at room
temperature for 30 minutes using the VectaStain Elite
ABC kit (Vector Laboratories, Burlingame, California,
USA). 3,3-Diaminobenzidine was used as Chromagen
and was applied according to the manufacturer’s direc-
tions (Roche Molecular Biochemicals, Indianapolis,
Indiana, USA). Gill’s hematoxylin was used to counter-
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stain the tissue. Sections were incubated with PBS in
place of primary Ab as negative control.
RT-PCR analysis of transgene expression. Total RNA was
isolated from multiple tissues in transgenic and wild-
type mice. First-strand cDNA was generated using 5 µg
total RNA, 200 U of Moloney murine leukemia virus
reverse transcriptase (Life Technologies Inc., Rockville,
Maryland, USA), and 200 ng of random primers (Life
Technologies Inc.) in a total volume of 30 µl. PCR
included the following sets of primers. The first set
detected expression of the transgene’s human cyclin D1
sequences: sense primer, 5′-GAACAAACAGATCATCCG-
CAA-3′ (exon 3), antisense primer, 5′-CCCTTCTGGTAT-
CAAAATGC-3′ (exon 5), amplifying a 475-bp fragment
during 30 cycles of 60 seconds of denaturation at 94°C,
60 seconds of annealing at 57°C, and 60 seconds of
extension at 72°C. RT-PCR for mouse β-actin and
mouse PTH were also performed to ensure that the tem-
plate cDNA was intact and, for the parathyroid/neck
region, to confirm the presence of parathyroid-derived
RNA/cDNA. Thus, the second primer set detected
expression of the mouse PTH gene: sense primer, 5′-
GTGATGATCATCATGCTGGCA-3′ (exon 2), antisense
primer, 5′-TTTAACTAATACATCCACATC-3′ (exon 3),
amplifying a 306-bp fragment during 35 cycles of 60
seconds of denaturation at 94°C, 60 seconds of anneal-
ing at 55°C, and extension for 60 seconds at 72°C. The
third set detected mouse β-actin gene expression: sense
primer, 5′-GTGGGCCGCTCTAGGCACCA-3′, antisense
primer, 5′-CGGTTGGCCTTAGGGTTCAGGGGG-3′, ampli-
fying a 244-bp fragment during 30 cycles of 60 seconds
of denaturation at 94°C, 45 seconds of annealing at
60°C, and extension for 45 seconds at 72°C. PCR prod-
ucts were analyzed on a 3% agarose gel. The authentici-
ty of RT-PCR products was verified by direct DNA
sequencing. These bands were never detected in reac-
tions without reverse transcriptase.
Assessment of parathyroid cell proliferation using 5′-bromo-
2′-deoxyuridine and proliferating cell nuclear antigen. Two
PTH–cyclin D1 transgenic mice and two wild-type litter-
mates, 10 months old, were fed a standard diet and
water containing 5 mg/ml 5′-bromo-2′-deoxyuridine
(BrdU; Sigma Chemical Co., St. Louis, Missouri, USA).
After 5 days, the mice were sacrificed, and the thyroid-
parathyroid complex was dissected, fixed in 4%
paraformaldehyde for 1 hour, and saturated overnight
with 30% sucrose. The tissue was embedded in OCT
medium, and 5-µm-thick axial sections were obtained.
Cells that had incorporated BrdU were identified using
a BrdU immunostaining kit (Zymed Laboratories Inc.,
South San Francisco, California, USA). Slides were incu-
bated for 10 minutes in methanol containing 3% hydro-
gen peroxide to quench endogenous peroxidase and
rinsed in PBS for 2 minutes, three times. Sections were
digested with 0.1% trypsin for 15 minutes in a moist
chamber at 37°C, rinsed in distilled water three times
for 2 minutes each time, and incubated for 30 minutes
at room temperature with Zymed Laboratories Inc.
denaturing solution to denature DNA. The slides were
rinsed in PBS for 2 minutes three times and incubated
for 15 minutes at room temperature with Zymed Labo-
ratories Inc. blocking solution to reduce nonspecific
binding. Sections were then incubated with biotinylat-
ed mouse anti-BrdU Ab at room temperature for 2
hours. Excess Ab was rinsed off with PBS, and the
bound Ab was detected by the streptavidin-biotin
immunoperoxidase method. Sections were stained with
diaminobenzidine and counterstained with hema-
toxylin. Cells with brown nuclear staining were scored
as having incorporated BrdU.
Proliferating cell nuclear antigen (PCNA) was
detected using a PCNA immunostaining kit (Zymed
Laboratories Inc.). Slides were incubated for 10 min-
utes in methanol containing 3% hydrogen peroxide to
quench endogenous peroxidase and rinsed in PBS for
2 minutes, three times. Sections were incubated for 30
minutes at room temperature with Zymed Laborato-
ries Inc. blocking solution to reduce nonspecific bind-
ing, followed by incubation with biotinylated mouse
anti-PCNA Ab at room temperature for 2 hours.
Excess Ab was rinsed off with PBS, and the bound Ab
was detected by the streptavidin-biotin-immunoper-
oxidase method and counterstained as described
above. PCNA-positive cells were scored as having
brown nuclear staining.
Bone histology and histomorphometry. Mice at 22 months
of age received intraperitoneal injections of 10 mg/kg of
calcein 12 and 2 days before sacrifice. The calvaria were
dissected free of tissue, and calvaria were cut in half
through the central suture. One-half of the calvaria of
each mouse were fixed in 4% paraformaldehyde at 4°C,
decalcified in 15% EDTA, dehydrated in increasing con-
centrations of ethanol, cleared in xylene, and embedded
in paraffin. The other half calvaria were fixed in 70%
ethanol at 4°C, dehydrated in increasing concentrations
of ethanol, cleared in xylene, and embedded in methyl-
methacrylate. Paraffin-embedded bones were sectioned
and 5-µm sections were stained for tartrate-resistant
acid phosphatase (TRAP) according to the method of
Bancroft (20), and counterstained with hematoxylin.
Osteoclasts were identified by TRAP staining and by
their characteristic morphology, namely multiple nuclei
and localization next to the mineralized matrix. Methyl-
methacrylate-embedded bones were sectioned, and 
5-µm sections were deplastified and left unstained. Sta-
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Figure 1
Structure of the PTH–cyclin D1 transgene. The 5.2-kb BglII–BglII 5′–reg-
ulatory fragment of the human PTH gene consists of the 5.1-kb 5′-flank-
ing sequence (black) and the first 66 bp of untranslated exon 1 (gray).
The 16-kb human genomic cyclin D1 component included all five exons,
all four introns, 1.1-kb 5′-flanking region, and 1-kb 3′-flanking region.
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tic and dynamic histomorphometry was
performed on 18- to 23-month-old
PTH–cyclin D1 transgenic and wild-type
mice. Histomorphometric analyses were
performed in a blinded, nonbiased man-
ner using the BIOQUANT computer-
ized image analysis system (BIO-
QUANT-R & M Biometrics, Nashville,
Tennessee, USA). The measurements,
terminology, and units that were used
for histomorphometric analysis were
those recommended by the Nomencla-
ture Committee of the American Society
for Bone and Mineral Research (21).
Blood chemistry analyses. Blood was col-
lected by tail nicking or by terminal
cardiac puncture. Serum calcium levels
were measured by a calcium assay
(Sigma Chemical Co.) using the 
o-cresolphthalein-complexone method
(22). Serum phosphorus, albumin, and
creatinine levels were measured by an
autoanalyzer. Serum PTH levels were
measured using the rat PTH immuno-
radiometric assay (Nichols Institute,
San Juan Capistrano, California, USA).
Measurement of PTH response to variation
in serum calcium concentration. After fast-
ing 5–6 hours, mice were administered a
single intraperitoneal injection of calci-
um gluconate or EDTA. The doses of
calcium gluconate were 75, 150, and 300
µmol/kg body weight (BW). The doses
of EDTA were 75, 150, 300, and 500
µmol/kg BW. If hypocalcemia was not
achieved with 500 µmol/kg BW, addi-
tional doses of EDTA (750 and 900
µmol/kg) were administered. Blood was
collected by tail nicking 30 minutes
after injection. Serum was collected
once a day, on 8 consecutive days for
each mouse. Nonlinear mixed effects
models were used to fit the sigmoidal
curve of Brown (23).
Immunohistochemical analysis of calcium-
receptor expression in parathyroid gland.
Frozen sections of mouse thyroid gland
with adherent parathyroid gland(s)
were prepared, and those containing
parathyroid tissue were identified by
standard hematoxylin and eosin stain-
ing. The parathyroid gland–containing
sections were air-dried at room temper-
ature. After treatment with an endoge-
nous peroxidase inhibitor (DAKO
Corp., Carpinteria, California, USA), the
slides were blocked with 1% (wt/vol)
BSA in PBS for 30 minutes, and
immunostaining was performed as
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Figure 2
Transgene expression and histologic examination of parathyroid glands from
PTH–cyclin D1 transgenic and wild-type mice. Serial sections were cut to a thickness of
5 µm and processed either for morphological hematoxylin/eosin (a–d) or in situ
hybridization (e– h). (b) PC1 mice (×25, 12 months old) and (c) PC2 mice (×25, 12
months old) exhibited marked parathyroid hypercellularity in comparison with (a)
wild-type mice (×25, 12 months old). (d) In addition, an example of a gland with the
appearance of a parathyroid adenoma with a multilobular pattern is shown (PC2
mouse, 22 months old, ×10). A compressed rim of normal tissue is seen along the left
upper face of this tumor (marked with arrow), but not in a, b, or c. In situ hybridiza-
tion for the human cyclin D1 gene was performed using complementary 35S-labeled
riboprobes (17), which were transcribed from the plasmid containing the human cyclin
D1 cDNA (pPL-8) (4). Dark-field views counterstained with hematoxylin and eosin are
shown. Parathyroid tissue is visualized in pink, and thyroid tissue appears light green.
(e and f) Parathyroid gland from 12-month-old wild-type mouse. (g and h) Parathy-
roid gland from 12-month-old PC2 mouse. (e and g) In situ hybridization with 
antisense human cyclin D1 probe. (f and h) In situ hybridization with negative control
sense human cyclin D1 probe. The histologic identification of parathyroid glands was
confirmed by in situ hybridization for PTH gene expression using a rat PTH plasmid
template and riboprobe (data not shown).
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described previously (24, 25) by sequential application
of primary antiserum (overnight at 4°C with 5 µg/ml
of affinity-purified, polyclonal anti-calcium receptor
[anti-CaR] antiserum 4637) and then secondary Ab (1
hour at room temperature with peroxidase-conjugated
goat, anti-rabbit IgG) in blocking solution, and finally
use of the DAKO 3-amino-9-ethylcarbazole (AEC) sub-
strate system. Photomicrographs were taken at ×100
and ×400. To document the specificity of the
immunostaining, the anti-CaR antiserum was prein-
cubated with the peptide against which it was raised
(corresponding to amino acids 345–359 of the bovine
CaR) before performing immunohistochemistry as just
described. Abolition of CaR immunoreactivity when
the antiserum had been peptide blocked indicated that
the immunostaining was specific for the immunogenic
peptide sequence, which is present in all mammalian
CaRs examined to date.
Results
A total of six independent founder PTH–cyclin D1 trans-
genic mice were generated, four of which successfully
transmitted the transgene to progeny. Three transgenic
lines, PC1, PC2, and PC4, were analyzed in this study,
selected to represent a range of transgene copy num-
bers and to assure that any phenotype was qualitative-
ly independent of the specific transgene integration site
for that line. The estimated transgene copy numbers of
lines PC1, PC2, and PC4 were approximately 3, 11, and
15, respectively (data not shown). Strong expression of
the cyclin D1 transgene in parathyroid tissue was con-
firmed by using in situ hybridization (Figure 2) and
immunohistochemistry (Figure 3). After confirming
similarity of the phenotype in all lines (below), PC1 and
PC2 lines were selected for further detailed studies.
A survey of other transgenic mouse tissues for expres-
sion of the cyclin D1 transgene was performed by RT-
PCR analysis with primers that reside in exons 3 and 5
of the human cyclin D1 gene (see Methods). Because the
primer-binding sequences in the human transgene
product are very different from the corresponding
region in mouse cyclin D1, this assay was designed to
specifically detect transcripts from the transgene, as
opposed to endogenous murine cyclin D1 transcripts or
product amplified from contaminating genomic DNA;
this specificity was confirmed by direct sequencing of
the PCR product. The expected expression in the
parathyroid/neck region was observed, and no trans-
gene expression was found in any of the other exam-
ined tissues including brain, thymus, heart, lung, liver,
spleen, kidney and bone/calvaria, with the exception of
testis (not shown). The ectopic expression in testis was
minimal as it was not detectable by in situ hybridiza-
tion (not shown); testes from these mice exhibited no
histological abnormalities. The thymus was grossly and
histologically normal, and no obvious lesions were
present in the hypothalamus; these tissues have been
reported to express PTH ectopically in native animals
(26, 27). Thus, the 5.2-kb 5′-regulatory region of the
human PTH gene appropriately targets high-level
transgene expression specifically to parathyroid cells.
Transgenic and wild-type littermates demonstrated
no significant differences in morphology, weight, or
growth. The ratio of transgenic to wild-type mice was
1:1, as expected. Transgenic mice grew normally,
showed no differences in weight as compared with
wild-type mice, have lived longer than 2 years without
any sign of abnormality, and were fertile.
Comparisons of biochemical phenotypes across wild-
type and transgenic mouse genotypes for 18- to 27-
month-old mice (mean ages 21.0–23.1) were done using
Kruskal Wallis and Mann-Whitney nonparametric rank
tests. PC1, PC2, and PC4 transgenic mice were similar
in terms of body weight, serum calcium, phosphorus,
creatinine, and PTH levels. Wild-type mice were similar
in body weight, serum albumin, and creatinine levels to
the transgenic mice, but transgenic mice had signifi-
cantly higher levels of serum calcium (PC2: median
11.65 mg/dl vs. 9.2 mg/dl, P < 0.0001; PC1: median
12.45 mg/dl, P < 0.001; PC4: median 11.4 mg/dl, 
P < 0.001) and PTH (PC2: median 140 pg/ml vs. 44
pg/ml, P = 0.006; PC1: median 115 pg/ml, P < 0.001;
PC4: median 150 pg/ml, P < 0.001) than wild-type mice.
Similarly, PC2 mice also had significantly lower levels of
serum phosphorus (median 6.0 mg/dl vs. 7.2 mg/dl, 
P = 0.01) than wild-type mice. In terms of time course,
we discerned a trend toward higher calcium and PTH
levels in the transgenic mice starting at 4–6 months of
age; by 12–13 months of age those differences became
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Figure 3
Immunohistochemical analysis of cyclin D1 expression. (a) Parathy-
roid gland from a 12-month-old wild-type mouse showing no stain-
ing. Parathyroids of wild-type mice were uniformly negative for cyclin
D1 staining. (b) Parathyroid gland from a 10-month old PTH–cyclin
D1 transgenic (PC2) mouse. Staining (dark brown) is localized to the
nucleus and is distributed nonuniformly throughout the parathyroid.
Adjacent thyroid tissue is negative for staining. The same pattern of
expression was common to other PC2 mice.
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significant (data not shown). All transgenic mice had
normal serum creatinine levels indicating that the
increased levels of serum calcium and PTH were not due
to secondary/tertiary hyperparathyroidism of uremia
and that the mild chronic primary hyperparathyroidism
did not cause major end-organ damage to the kidneys.
Examination of the parathyroid glands from 1-year-
old transgenic mice revealed a marked increase of glan-
dular size and hypercellularity suggesting hyperplasia
(Figure 2). Based on the maximum diameter of the
glands visualized on serial sections and the number of
sections in which the glands were visualized, the size of
the parathyroids in transgenic mice was estimated to be
increased more than two- to threefold
in PC1 and PC2 lines, respectively.
Furthermore, in one cohort at ages
greater than 18 months, 3 of 11 trans-
genic PC1 mice and 3 of 11 transgenic
PC2 mice exhibited histologic features
suggestive of adenoma; Figure 2d
shows such an adenomatous-appear-
ing parathyroid with a multilobular,
tubular pattern, which was encapsu-
lated, compressed surrounding nor-
mal parathyroid tissue, and contained
chief cells with more cytoplasm than
normal. In addition, the size of
parathyroid tumors within the same
transgenic animal often exhibited
considerable asymmetry. In one group
of transgenic mice age 19–27 months,
10 of 17 mice (59%) for which two
parathyroids could be identified
exhibited such asymmetry, raising the
possibility of adenomatous out-
growth on the expected hyperplastic
cellular milieu. While none of these
criteria or observations can be consid-
ered proof that a clonal tumor (ade-
noma) was present, the findings do
suggest that it may be fruitful to also
seek stochastic acquired alterations in
oncogenes/tumor-suppressor genes
other than cyclin D1 as contributors to parathyroid
tumorigenesis in these mice, just as is the case for
human parathyroid tumors (28). Mitoses, typically
found in human parathyroid carcinomas, but not ade-
nomas, were not observed in parathyroid tumors from
PTH–cyclin D1 mice. Neither parathyroid hyperplasia
nor apparent adenomas were observed in wild-type mice.
Multiple organs of all sacrificed mice were carefully
examined, and histological analyses were systematically
carried out on 15 transgenic mice, with all other tissues
including testis, thymus, brain, kidney, lung, liver, and
bone being grossly normal. No osteosarcomas were
observed. No metastases were seen.
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Figure 4
Analysis of parathyroid cell proliferation using immunohistochemical detection of BrdU incorporation. (a) Wild-type mouse parathyroid,
negative for BrdU incorporation. (b) PTH–cyclin D1 transgenic mouse parathyroid with BrdU-positive cells marked by dark-brown nuclear
staining. Positive cells were nonuniformly scattered through the gland.
Figure 5
Bone histology and histomorphometry in PTH–cyclin D1 transgenic mice. Paraffin-embedded
bones from mice at 22 months of age were sectioned, and 5-µm sections were stained for
TRAP according to the method of Bancroft (20) and counterstained with hematoxylin. Osteo-
clasts were identified by TRAP staining and by their characteristic morphology, namely multi-
ple nuclei and localization next to the mineralized matrix. More osteoclasts (arrows) and 
marrow spaces were found in the PC2 mice (×225) (b) compared with the wild-type mice
(×225) (a). These images signify increased bone resorption in the PC2 mice. Methyl-
methacrylate-embedded bones were sectioned, and 5-µm sections were deplastified and left
unstained. (c) PC2 calvaria (×250) demonstrated wider and increased double-labeled surfaces
with wider bands (arrows) in the marrow spaces than the calvaria from wild-type mice (×250)
(d). The labeling pattern in the PC2 mice suggested increased bone formation.
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To examine more directly the basis of cyclin
D1–induced parathyroid hypercellularity, we assessed
parathyroid cell proliferative rates in transgenic mice
and controls. First, we compared the incorporation of
BrdU in parathyroid cells of PTH–cyclin D1 mice with
that in wild-type littermates. As described in Methods,
animals were provided drinking water containing BrdU
for 5 days. Proliferating cells that actively incorporated
BrdU were identified by immunostaining with an anti-
BrdU Ab. Parathyroid tissue from PTH–cyclin D1 mice
showed the presence of numerous BrdU-positive cells
scattered throughout the gland in a nonuniform pat-
tern. In contrast, BrdU incorporation was absent in
parathyroid glands from wild-type mice (Figure 4). Sim-
ilar results were obtained with immunostaining with an
Ab to PCNA, another marker of cellular proliferation
(not shown). Immunostaining patterns for BrdU and
PCNA closely matched those for cyclin D1 on contigu-
ous sections (Figures 3 and 4). As an internal control,
the majority of the rapidly proliferating basal cells of the
esophageal epithelium showed positive dark-brown
nuclear BrdU and PCNA immunostaining in both
transgenic and wild-type mice (data not shown). Thus,
these experiments clearly documented abnormally
increased parathyroid-cell proliferation due to parathy-
roid-targeted overexpression of cyclin D1.
Histomorphometric studies of bone biopsy speci-
mens in patients with primary hyperparathyroidism
have demonstrated both a high turnover state and
cortical bone loss (29). Compared with wild-type
mice, PTH–cyclin D1 transgenic mice have decreased
bone volume and evidence of increased bone turnover
with increased numbers of osteoclasts and bone for-
mation in the calvaria (Figure 5). Static histomor-
phometry showed that 18- to 23-month-old PC2 mice
had decreased total bone volume percentage,
increased bone marrow area/total tissue area, and
increased osteoclast numbers/bone area (Figure 6a).
Dynamic histomorphometry for bone formation
parameters (Figure 6b) demonstrated that PTH–cyclin
D1 mice had significant increases in percentage of
mineralized perimeter, mineral apposition, and bone
formation rates compared with the age-matched wild-
type mice. This high-turnover phenotype, therefore,
had marked similarities with human bone under the
influence of excess PTH. No ectopic expression of the
cyclin D1 transgene was detected in bone or bone
marrow by RT-PCR and immunohistochemical analy-
ses (data not shown), further supporting the conclu-
sion that the bone phenotype was the result of these
animals’ primary hyperparathyroidism.
We examined the relationship between ambient calci-
um and parathyroid gland function by determining
whether PTH–cyclin D1 mice could modulate serum
PTH levels in response to changes in serum calcium
concentration (Figure 7). Negative relationships
between serum calcium and PTH were shown for both
PC2 and wild-type mice. Linear regression analyses
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Figure 6
Static and dynamic bone histomorphometry in PTH–cyclin D1 trans-
genic mice. (a) Static and (b) dynamic histomorphometry was per-
formed on 18- to 23-month-old PTH–cyclin D1 transgenic (PTH-D1)
and wild-type (WT) mice. For each histomorphometric parameter,
PTH-D1 mice were significantly different from WT (P < 0.05). Bars,
means ± SEM. TBV, total bone volume percentage; BMA/TTA, bone
marrow area/total tissue area; OC#/B Ar, osteoclast number/bone
area; % Min per, percentage mineralizing perimeter; MAR, mineral
apposition rate; and BFR, bone formation rate.
Figure 7
Altered PTH response to variation in serum calcium concentration in
PTH–cyclin D1 transgenic mice. After fasting 5–6 hours, mice were
administered a single intraperitoneal injection of calcium gluconate
or EDTA. The doses of calcium gluconate were 75, 150, and 300
µmol/kg BW. The doses of EDTA were 75, 150, 300, and 500
µmol/kg BW. If hypocalcemia was not achieved with 500 µmol/kg
BW, additional doses of EDTA (750 and 900 µmol/kg) were admin-
istered. Blood was collected by tail nicking 30 minutes after injection.
Serum was collected once a day, on 8 consecutive days, for each
mouse. Serum calcium levels were measured by a calcium assay
(Sigma Chemical Co.) using the o-cresolphthalein-complexone
method (22). Observations on PC2 mice are indicated by open dia-
monds; observations on wild-type mice are indicated by filled dia-
monds. Nonlinear mixed effects models were used to fit the sigmoidal
curve of Brown (23). The dashed line A is the fitted curve for the PC2
mice, excluding one mouse (number 823) with extraordinary values
(see Results); the solid line B is the fitted curve for the wild-type mice.
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using calcium to predict PTH performed on these data
indicated high correlation coefficients: for the six wild-
type mice, within-mouse correlations ranged from 0.80
to 0.97, and for the ten PC2 mice the correlations
ranged from 0.74 to 0.97. Nine of the ten PC2 mice had
an altered relationship, which was shifted upward and
to the right and was steeper relative to that in the wild-
type mice; the other PC2 mouse, mouse 823, had only
three observations recorded, with no serum calcium
level below 12.6 mg/dl. There was much greater hetero-
geneity in the PTH/calcium relationship among the
PC2 mice than the wild-type mice, but the direction of
the association was the same for all PC2 mice other than
the aforementioned mouse 823. The fitted values for
the regression lines were larger for every PC2 mouse
than for any wild-type mouse for all serum calcium lev-
els less than 9.95 mg/dl; at only one observation at a sin-
gle time point did any wild-type mouse have a serum
calcium level higher than this. The intercepts on the
PTH axis were larger (P = 0.0075, Mann-Whitney test)
and slopes steeper (P = 0.0075, Mann-Whitney test) for
the PC2 mice (median intercept 837.4 pg/ml at serum
calcium 4.0 mg/dl, median slope –116.4) than for the
wild-type mice (median intercept 242.4, median slope
–43.83). Nonlinear mixed-effects models (30) were used
to fit the sigmoidal model of Brown (23) to the PC2 and
wild-type mice data; Figure 7 shows the fitted curves.
These observations indicate that the abnormal trans-
genic parathyroids retain the capacity to regulate their
secretion of PTH by suppression in the face of enforced
increases in serum calcium, and despite the transgenics’
baseline hypercalcemia in vivo their parathyroid cells are
not at or near a maximally suppressed output of PTH.
Thus, the biochemical phenotype of PTH–cyclin D1
transgenic mice is strongly reminiscent of the abnor-
malities in calcium-PTH set point determined in vivo in
patients with primary hyperparathyroidism (2).
Finally, we examined the level of expression of the
CaR in the parathyroids of PTH–cyclin D1 transgenic
mice and controls (Figure 8), because the CaR is a key
regulator of calcium-regulated PTH release, and
decreased CaR expression has been reported in human
parathyroid tumors. The intensity of CaR immunore-
activity was, indeed, substantially less in the transgenic
than in the normal parathyroid (Figure 8, c and d,
respectively), consistent with reduced expression of
receptor protein in the former and comparable to that
found in pathological parathyroid glands from
patients with primary hyperparathyroidism.
Discussion
Abnormal cell proliferation and abnormal control of
PTH release are concomitant and seemingly
omnipresent properties of parathyroid neoplasms. It
has been proposed that the only way to explain this
concordance, plus the low mitotic rate and long-term
clinical/biochemical stability of most parathyroid ade-
nomas is through a primary-acquired mutation in the
PTH secretory set-point pathway, with all other
described genetic changes being secondary phenome-
na (3, 31, 32). While it is appealing to speculate that a
defect within a set-point control gene could be the
major factor leading to parathyroid proliferation in
common sporadic primary hyperparathyroidism, no
such evidence currently exists. Indeed, the development
of parathyroid tumors in transgenic mice with parathy-
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Figure 8
CaR immunoreactivity in sections of parathyroid
gland from transgenic and wild-type mice. (a and b)
Hematoxylin and eosin staining of a frozen section
of a parathyroid gland from a representative trans-
genic mouse (a), again shown to be enlarged, and a
wild-type mouse (b). The homogeneously staining
parathyroid gland in the middle portion of each
panel is surrounded by thyroid follicles. ×100. (c and
d) CaR immunoreactivity in the parathyroid glands
shown in a and b, respectively, as assessed using
anti-CaR antiserum 4637 and the immunoperoxi-
dase technique as described in Methods. There is
rim staining of the parathyroid chief cells from the
normal gland (d), suggesting expression of CaR pro-
tein in the plasma membrane that is substantially
more intense than that in the parathyroid gland
from the transgenic mouse (c). (e and f) Preabsorp-
tion of the anti-CaR antiserum with the peptide
against which it was raised abolishes the immunore-
activity (e, transgenic; f, normal), documenting that
the staining is CaR specific. (c–f) ×400.
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roid-targeted cyclin D1 oncogene overexpression indi-
cates that the hormonal regulatory defect need not be
primary, but can result secondary to a primary distur-
bance in cellular-growth control. Furthermore, the
development of this murine model of primary hyper-
parathyroidism will be a useful tool for genetically dis-
secting the link between these pathways.
Abnormal regulation of PTH secretion by serum cal-
cium contributes importantly to the pathophysiology
of hypercalcemia in parathyroid adenoma (33, 34), and
the observed decrease in expression of the CaR in the
parathyroid tissue of PTH–cyclin D1 transgenic mice
may well contribute to their increased calcium-PTH set
point. Strikingly, this reduction in CaR immunoreac-
tivity appears comparable to that found in pathological
parathyroid glands from patients with primary and
severe uremic secondary/tertiary hyperparathyroidism
(24, 35, 36). Decreased CaR expression is thought to
contribute to the elevation in set-point in these two
forms of hyperparathyroidism as it does in mice het-
erozygous or homozygous for targeted disruption of the
CaR gene (37) and in humans with inherited inactivat-
ing CaR mutations (38). It is of note that severe
homozygous or rare heterozygous defects in calcium
sensing can also promote parathyroid proliferation (37,
38, 39). However, no primary somatic mutations with-
in the CaR gene have been found in sporadic parathy-
roid tumors (40), and the mechanism underlying the
reduced expression of the CaR in pathological parathy-
roid glands is not known. Importantly, our observations
now provide evidence that cyclin D1 overexpression can
induce, directly or indirectly, such a decrease in parathy-
roid CaR. This finding further validates the PTH–cyclin
D1 mouse as a model of human hyperparathyroidism,
and provides an experimental system in which the
molecular basis for reduced CaR expression (and/or
other components of the set-point pathway) and its role
in the pathophysiology of sporadic hyperparathy-
roidism can be scrutinized.
The development of this transgenic model has addi-
tional significance on several fronts. First, the apparent
adenomas that evolve in some animals may well be
monoclonal neoplasms, and their examination for spe-
cific acquired genetic defects — e.g., by loss of heterozy-
gosity (LOH), comparative genomic hybridization,
and/or microarray methods — could aid in the identifi-
cation of cognate genes important in the pathogenesis
of human parathyroid adenomas. Second, the success-
ful targeting of transgene expression to the parathy-
roids indicates that the PTH gene’s major tissue-specif-
ic enhancer(s) lies within the proximal 5 kb of its 5′
regulatory region. Because of the absence of any differ-
entiated parathyroid cell line for use in transfection
analyses with reporter constructs, the location of a
strong parathyroid-targeting sequence has heretofore
remained unknown. The targeting sequence from the
PTH–cyclin D1 transgene should be useful for the selec-
tive expression of other gene products in parathyroid
tissue, including molecules such as the Cre recombinase
to effect tissue-specific knockouts, for example, thereby
expanding our opportunities for insights into the phys-
iology and tumor biology of the parathyroids. Third, lit-
tle is known about the mechanism through which over-
expressed cyclin D1 exerts its oncogenicity in the
parathyroid tissue context, and PTH–cyclin D1 mice will
permit examination of this issue. Finally, this model
provides an attractive system by which the effect of PTH
on bone in hyperparathyroid states can be dissected. For
example, mice with genetically engineered abnormali-
ties in molecules that are candidates for mediating PTH
action on bone could be mated with the PTH–cyclin D1
transgenic mice and be examined for changes in the
bone phenotype. The importance of this issue is height-
ened by the emergence of osteopenia and diminished
bone density as the major indication for treatment of
primary hyperparathyroidism in the modern era.
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